Screener
Maze Therapeutics MAZE Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Maze Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Maze Therapeutics’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:48 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344903
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Proceeds from initial public offering, net | — | 130,200 |
| Payment of initial public offering costs | — | (2,448) |
| Payment of success fee derivative | — | (500) |
| Net cash provided by financing activities | 189,793 | 127,990 |
| Net increase in cash, cash equivalents and restricted cash | 13,396 | 67,730 |
| Cash, cash equivalents and restricted cash at beginning of the period | 190,335 | 197,900 |
| Cash, cash equivalents and restricted cash at end of the period | $203,731 | $265,630 |
| Reconciliation to cash, cash equivalents and restricted cash: |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Maze Therapeutics's financing cash flow?
- Maze Therapeutics (MAZE) reported financing cash flow of $147.44M in Q2 2026.
- How has Maze Therapeutics's financing cash flow changed year-over-year?
- Maze Therapeutics's financing cash flow increased by 23990.8% year-over-year, from $612K to $147.44M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Maze Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude